EMBER-4: a Phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy in patients with ER+, HER2− early breast cancer with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
Senologie - Zeitschrift für Mammadiagnostik und -therapie | July 12, 2023 | Volume: 20 | Issue: 02 | Pages: e6-e7
10.1055/s-0043-1769141